Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
13.99
-0.39 (-2.71%)
Apr 29, 2026, 2:09 PM EDT - Market open
Vor Biopharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 396.49 | 81.95 | 31.36 | 57.71 | 119.8 | Upgrade
|
| Short-Term Investments | 58.72 | 9.98 | 105.82 | 172.54 | 87.67 | Upgrade
|
| Cash & Short-Term Investments | 455.21 | 91.93 | 137.18 | 230.25 | 207.47 | Upgrade
|
| Cash Growth | 395.19% | -32.99% | -40.42% | 10.98% | 327.43% | Upgrade
|
| Prepaid Expenses | 1.15 | 4.2 | 3.15 | 4.37 | 4.84 | Upgrade
|
| Other Current Assets | 1.75 | 0.38 | 0.48 | 2.34 | 2.09 | Upgrade
|
| Total Current Assets | 458.11 | 96.51 | 140.8 | 236.95 | 214.4 | Upgrade
|
| Property, Plant & Equipment | 3.47 | 41.59 | 50.1 | 57.08 | 22.52 | Upgrade
|
| Other Long-Term Assets | 2.55 | 4.8 | 7.23 | 5.34 | 5.67 | Upgrade
|
| Total Assets | 464.13 | 142.89 | 198.13 | 299.37 | 242.59 | Upgrade
|
| Accounts Payable | 5.13 | 1.51 | 0.82 | 1.77 | 1.55 | Upgrade
|
| Accrued Expenses | 19.76 | 12.89 | 10.93 | 8.08 | 6.34 | Upgrade
|
| Current Portion of Leases | 0.28 | 4.22 | 3.83 | 3.27 | 1.84 | Upgrade
|
| Other Current Liabilities | - | - | - | - | 0.43 | Upgrade
|
| Total Current Liabilities | 25.17 | 18.61 | 15.57 | 13.12 | 10.15 | Upgrade
|
| Long-Term Leases | 2.72 | 27.62 | 31.83 | 35.64 | 16.17 | Upgrade
|
| Other Long-Term Liabilities | 600.55 | - | - | - | - | Upgrade
|
| Total Liabilities | 628.44 | 46.23 | 47.4 | 48.76 | 26.33 | Upgrade
|
| Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 988.6 | 553.62 | 490.87 | 473.59 | 346.38 | Upgrade
|
| Retained Earnings | -1,153 | -456.99 | -340.08 | -222.22 | -130.12 | Upgrade
|
| Comprehensive Income & Other | 0.04 | 0.02 | -0.08 | -0.77 | - | Upgrade
|
| Total Common Equity | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 | Upgrade
|
| Shareholders' Equity | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 | Upgrade
|
| Total Liabilities & Equity | 464.13 | 142.89 | 198.13 | 299.37 | 242.59 | Upgrade
|
| Total Debt | 3 | 31.83 | 35.66 | 38.91 | 18.01 | Upgrade
|
| Net Cash (Debt) | 452.21 | 60.1 | 101.52 | 191.33 | 189.46 | Upgrade
|
| Net Cash Growth | 652.48% | -40.80% | -46.94% | 0.99% | 526.38% | Upgrade
|
| Net Cash Per Share | 45.81 | 17.49 | 30.22 | 96.75 | 113.33 | Upgrade
|
| Filing Date Shares Outstanding | 48.85 | 6.24 | 3.41 | 3.32 | 1.87 | Upgrade
|
| Total Common Shares Outstanding | 38.72 | 6.24 | 3.39 | 3.3 | 1.86 | Upgrade
|
| Working Capital | 432.93 | 77.9 | 125.23 | 223.83 | 204.25 | Upgrade
|
| Book Value Per Share | -4.24 | 15.49 | 44.40 | 75.95 | 116.35 | Upgrade
|
| Tangible Book Value | -164.31 | 96.66 | 150.72 | 250.61 | 216.26 | Upgrade
|
| Tangible Book Value Per Share | -4.24 | 15.49 | 44.40 | 75.95 | 116.35 | Upgrade
|
| Machinery | - | 17.15 | 17.4 | 15.64 | 8.77 | Upgrade
|
| Construction In Progress | - | 0.04 | 0.15 | 1.04 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.